Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,9438775,oral bioavailability,"Irbesartan has the highest oral bioavailability in its class (60% to 80%) and, unlike valsartan, its absorption is not affected by food.","The new angiotensin II receptor antagonist, irbesartan: pharmacokinetic and pharmacodynamic considerations. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9438775/),%,60,165770,DB01349,Tasosartan
,9438775,oral bioavailability,"Irbesartan has the highest oral bioavailability in its class (60% to 80%) and, unlike valsartan, its absorption is not affected by food.","The new angiotensin II receptor antagonist, irbesartan: pharmacokinetic and pharmacodynamic considerations. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9438775/),%,80,165771,DB01349,Tasosartan
,9438775,elimination half-life,"Irbesartan displays linear, dose related pharmacokinetics and, with the exception of tasosartan's active metabolite, has the longest elimination half-life of the AIIRA (11 to 15 h).","The new angiotensin II receptor antagonist, irbesartan: pharmacokinetic and pharmacodynamic considerations. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9438775/),h,11 to 15,165772,DB01349,Tasosartan
,10709151,area under the change in diastolic blood pressure curve,"For area under the change in diastolic blood pressure curve, the reduction was significantly greater after tasosartan + atenolol compared with that after atenolol alone (336 +/- 85 and 190 +/- 71 mmHg.24 h; p < 0.05 for combination and atenolol alone, respectively; mean +/- SEM).",A pharmacokinetic and pharmacodynamic study of the potential drug interaction between tasosartan and atenolol in patients with stage 1 and 2 essential hypertension. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10709151/),24·h·mmhg,336,218276,DB01349,Tasosartan
,10709151,area under the change in diastolic blood pressure curve,"For area under the change in diastolic blood pressure curve, the reduction was significantly greater after tasosartan + atenolol compared with that after atenolol alone (336 +/- 85 and 190 +/- 71 mmHg.24 h; p < 0.05 for combination and atenolol alone, respectively; mean +/- SEM).",A pharmacokinetic and pharmacodynamic study of the potential drug interaction between tasosartan and atenolol in patients with stage 1 and 2 essential hypertension. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10709151/),24·h·mmhg,190,218277,DB01349,Tasosartan
